Abbott Laboratories (ABT) 42.90 $ABT
Google's Calico in $500M Joint Venture with AbbVie - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:38PM CDT
Calico, Google's (GOOGL) year-old health startup is collaborating with biotechnology drugmaker, AbbVie, a spin-off from Abbott Laboratories (ABT), for a joint venture to formulate treatments for cancer and Alzheimer's.
Global Companion Diagnostic Technologies Market Opportunities and Forecasts 2013 - 2020
M2 - Thu Sep 04, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qr68q/global_companion) has announced the addition of the "Global Companion Diagnostic Technologies Market (Indication and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The global companion diagnostic market is expected to reach $3.5 billion by 2020, and it would grow at a CAGR of 20% from 2014 to 2020 Companion diagnostics market by indication is segmented into oncology, cardiovascular, CNS, autoimmune & inflammation, virology and others. Presently, majority of the companion diagnostics have been developed for cancer and thus, it is the major revenue generating segment in the overall CD indication market. Companion diagnostics have been developed for breast cancer, lung cancer, colorectal cancer, gastric cancer and melanomas. Companion diagnostics for breast cancer is the highest revenue generator mainly because there has been an increase in the incidences of breast cancer and many companion diagnostics have been developed for detection of the HER/neu biomarker for breast cancer. As of now, companion diagnostics for cardiovascular conditions, central nervous system conditions , inflammation and autoimmune diseases and viral diseases are very few, with a majority still in development stage; however, as more and more biomarkers are being discovered, there would be an increase in development of new companion diagnostics. Companion diagnostics market by technology is segmented into immmunohistochemistry and molecular diagnostics. Molecular diagnostics has been the most favored technology and it is expected that next generation sequencing and real-time PCR would drive the growth of this market owing to recent advancements in these technologies. KEY DELIVERABLES MARKET BY INDICATIONS - Oncology - Cardiovascular - Central Nervous System - Auto immune & Inflammation - Virology - Others MARKET BY TECHNOLOGY - Immunohistochemistry - Molecular diagnostics - In situ Hybridization - FISH - CISH - Real time PCR - Gene Sequencing COMPANY PROFILES - Abbott Laboratories - bioMerieux - Dako (Agilent Technologies) - Leica Microsystems - Life Technologies - Myriad Genetics - Qiagen - Resonance Health Ltd - Roche - Ventana Medical Systems For more information visit http://www.researchandmarkets.com/research/3q..._companion
RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
Abbott Laboratories Rises 1.26% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Sep 03, 3:57PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $42.35 to a high of $42.79. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $42.60 on volume of 4.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FDA: Little evidence to support testosterone drugs
By MATTHEW PERRONE - AP - Wed Sep 03, 2:18PM CDT
WASHINGTON (AP) — The Food and Drug Administration says there is little evidence that testosterone-boosting drugs taken by millions of American men are beneficial, though the agency is also unconvinced by studies suggesting the hormone carries serious risks.
Google's health startup forges venture with AbbVie
AP - Wed Sep 03, 1:09PM CDT
SAN FRANCISCO (AP) — Google's ambitious health startup is teaming up with biotechnology drugmaker AbbVie in a $500 million joint venture that will try to develop new ways to treat cancer and other diseases such as Alzheimer's.
Global Heart Valve Repair and Replacement Market 2014-2018 - Key Vendors are Abbott Laboratories, Edward Lifesciences, Medtronic & St. Jude Medical
M2 - Wed Sep 03, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4bq7ck/global_heart) has announced the addition of the "Global Heart Valve Repair and Replacement Market 2014-2018" report to their offering. The Global Heart Valve Repair and Replacement market to grow at a CAGR of 7.72 percent over the period 2013-2018. Heart valves are structures in the human heart which control the flow of blood during the cardiac cycle. A person affected with heart valve diseases such as valvular stenosis, valvular insufficiency or regurgitation, prolapse, and atresia requires the repair or replacement of the natural heart valves. Aortic valves cannot be repaired; therefore, it is replaced using prosthetic heart valves. However, the mitral, tricuspid, and pulmonary valves can be repaired as well as replaced depending on the diseased condition and functionality of these valves. Heart valve repair and replacement devices are used for repairing the diseased heart valves as well as for replacing the natural valves with prosthetic valves. One of the emerging trends in the market is the increase in the number of products approved by regulatory authorities such as the FDA and CE. Such products are considered to be safe for commercial use increasing their adoption rate. According to the report, the increase in the aging population is one of the major drivers in the market. The incidence of cardiac disorders is more prevalent among the aging population across the world and people above the age of 60 years affected by heart valve diseases is expected to contribute to the growth the market. Further, the report states that the potential risk of complications associated with the use of heart valve repair and replacement devices is proving to be a barrier to the adoption of these devices. Some of the complications are device migration, infection, thrombosis, and mortality. In terms of application, the Global Heart Valve Repair and Replacement market can be segmented into two: - Heart Valve Repair - Heart Valve Replacement Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Key Vendors - Abbott Laboratories - Edward Lifesciences - Medtronic - St. Jude Medical Other Prominent Vendors - AorTech - Boston Scientific - Colibri Heart Valve - CryoLife - Direct Flow Medical - JenaValve - MiCardia - Mitralign - Neovasc - On-X Life Technologies - Sorin - Symentis - ValveXchange For more information visit http://www.researchandmarkets.com/research/4b...obal_heart
Abbott Receives CE Mark for FreeStyle® Libre, a Revolutionary Glucose Monitoring System for People with Diabetes
PR Newswire - Wed Sep 03, 8:30AM CDT
Abbott (NYSE: ABT) today announced that it has received CE Mark (Conformite Europeenne) for its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for people with diabetes. The system eliminates the need for routine finger pricks1, reading glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days. In addition, no finger prick calibration is needed--a key differentiator from current continuous glucose monitoring systems. The system will be available in seven countries across Europe in the coming weeks.
Favourable Rulings, Upcoming Conferences, Clinical Study Results, Drug Availability, and Tender Offers - Research Reports on United Therapeutics, Illumina, AstraZeneca, Eli Lilly and Abbott
PR Newswire - Wed Sep 03, 8:20AM CDT
Today, Analysts Review released its research reports regarding United Therapeutics Corporation (NASDAQ: UTHR), Illumina, Inc. (NASDAQ: ILMN), AstraZeneca plc (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY) and Abbott Laboratories (NYSE: ABT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6174-100free.
LABS, Inc. Names Todd G. Johnson as President and Chief Executive Officer
Business Wire - Tue Sep 02, 2:57PM CDT
LABS, Inc., a Centennial-based comprehensive, highly accredited specialized clinical reference testing laboratory, announced it has appointed Todd G. Johnson, MBA, as President and Chief Executive Officer. Based at LABS, Inc. Centennial headquarters, Johnson's initial priorities will be to continue to grow the company, and ensure that the organization remains competitive within the market place.
Next Support Level for Abbott Laboratories (ABT) is $41.89
Comtex SmarTrend(R) - Tue Sep 02, 12:28PM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today below their pivot of $42.24 and have already reached the first level of support at $42.06. Analysts will be watching for a cross of the next downside pivot targets of $41.89 and $41.54.
Fitch Maintains CFR's IDRs on Rating Watch Positive
Business Wire - Fri Aug 29, 12:47PM CDT
Fitch Ratings maintains CFR Pharmaceuticals S.A. and its subsidiary CFR International SpA on Rating Watch Positive in anticipation of their acquisition by Abbott Investments Luxembourg S.A.R.L., a subsidiary of Abbott Laboratories (Abbott; rated 'A+' by Fitch). A complete list of rating actions follows at the end of this press release.
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery
Global Infant Formula Market Report: Focus on China 2014
M2 - Thu Aug 28, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/twqn7f/global_infant) has announced the addition of the "Global Infant Formula Market Report: Focus on China" report to their offering. The market for infant formula products is one of the major and the fastest growing segments of the overall baby foods industry. Infant formula is either a partial or a total substitute for breast milk for infants and is recommended for feeding during the first twelve months. Since the start of the millennium, international awareness regarding the importance of early childhood nutrition has been on the rise. All over the world parents are becoming more concerned about the nutritional benefit of pediatric foods and breast-milk supplements. Increasing proportion of women participation in labor force and increased affordability supported by waning price responsiveness and a rise in disposable income across the world are the major factors that have helped the global IMF market to attain stronger growth levels. Though the market has been experiencing lower demand and growth from the traditional matured markets of the West stemming primarily from declining birth rate, the developing world, especially the Asia and Pacific region and Latin America have provided the headroom for the global market expansion. The market is dominated by the Asian region which consumes about three-fifths of the global IMF supplies. Particularly, China has gained the stature to maneuver the market single-handedly since the country alone accounts for about two-fifth of the global IMF market revenues. The report, Global Infant Formula Market prudently analyzes the development of the respective market, with a focus on the single largest market, China, and other regional but important markets. The report discusses the major trends, growth drivers as well as issues being faced by the industry. The global infant formula market is predominated by a handful of players including Nestl?, Danone, Mead Johnson Nutrition and Abbott which keep vying for greater market share. The profiles of these leading players are also included in the report along with their key financials and strategies for growth. . Key Topics Covered: 1. Market Overview 2. Baby Food/Infant Nutrition Market 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Abbott Laboratories - Danone S.A. - Mead Johnson Nutrition Co. - Nestl? S.A. For more information visit http://www.researchandmarkets.com/research/tw...bal_infant
Frustrating Boston Scientific Is Not What the Investor Ordered
at The Street - Thu Aug 28, 5:30AM CDT
It will only take one bad quarter for shares to fall to single digits. That's the only time you should buy.
Abbott Laboratories Has Returned 10.4% Since SmarTrend Recommendation (ABT)
Comtex SmarTrend(R) - Wed Aug 27, 10:05AM CDT
SmarTrend identified an Uptrend for Abbott Laboratories (NYSE:ABT) on April 22nd, 2014 at $38.75. In approximately 4 months, Abbott Laboratories has returned 10.39% as of today's recent price of $42.77.
Home Healthcare Global Market Report - Forecast to 2020 for the $300 Million Industry
M2 - Wed Aug 27, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lbsmjs/home_healthcare) has announced the addition of the "Home Healthcare Global Market - Forecast to 2020" report to their offering. Global home healthcare market is expected to reach more than $300 billion by 2019 growing at a CAGR of around 8.0% from 2014 to 2019 The home healthcare equipment market is expected to grow at a faster rate compared to home healthcare services market. Home healthcare is gaining a tremendous attention over hospitals for the sophistication, ease and privacy of treatment it offers. Increased in-hospital care cost, comfort of recovering at home and enhanced age-related chronic diseases in developing as well as developed countries are factors driving the overall growth of home healthcare market. Whereas factors such as poor technology adoption, weak reimbursement policies and rapidly changing technologies are hampering the market growth. Moreover, high capital costs, medical equipment, human resources and conventional model of business are the challenges faced by home healthcare market. The opportunities increasing the market trend is attributed to medical insurance by governments or organizations and cost-effectiveness.North America adopting novel technologies and portable diagnostic devices accounts for the largest share in the home healthcare market. While Europe with the presence of well-equipped healthcare reimbursement structure is the second leading market. Asia-Pacific is expected to grow at the highest CAGR driven by the aging population in countries such as India, China, and Japan. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Home Healthcare Therapeutic Equipment Market 5. Home Healthcare Services Market 6. Home Healthcare Telehealth Market 7. Regional Market Analysis 8. Company Developments 9. Major Company Profiles - Abbott Laboratories - Baxter International - Braun - Novo Nordisk - GE Healthcare - Invacare - Johnson and Johnson - Medtronic - Philips Healthcare - Roche Holding AG For more information visit http://www.researchandmarkets.com/research/lb...healthcare
Microfluidic Device System Market 2013 - 2019
M2 - Wed Aug 27, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x345bg/microfluidic) has announced the addition of the "Microfluidic Device System Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The global microfluidic device market was valued at USD 1,531.2 million in 2013. It is likely to grow at a CAGR of 22.8% during 2013 to 2019 to reach USD 5,246.4 million in 2019. Microfluidics is an evolving scientific field with numerous analytical applications and commercial potential. Globally, the microfluidic device market is witnessing significant growth due to increasing R&D investment in pharmaceuticals, life science and rising point of care testing demand. New trends in healthcare, such as healthcare at home, supports point of care testing (POCT) as the most efficient and effective delivery of healthcare. It has many applications in other areas such as drug screening, sugar testers, chemical micro reactor, microprocessor cooling and micro fuel cells. Rising demand for point of care testing, miniaturization of chip, and increasing demand for microfluidic devices in genomics and proteomics are the key growth drivers for the microfluidic device market. In addition, change in material mix would provide opportunity for new market entrants, which would further drive the growth of the microfluidic device market. North America was valued at USD 644.5 million in 2013 and is expected to reach USD 2,095.5 million in 2019, growing at a CAGR of 21.7% from 2013 to 2019. In-vitro diagnostics microfluidic device market was valued at USD 949.6 million in 2013 and is expected to reach USD 3,317.4 million in 2019, growing at a CAGR of 23.2% from 2013 to 2019. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Industry Analysis Chapter 4 Market Trends Chapter 5 Porters Five Force Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Segment Analysis - by Material Chapter 8 Segment Analysis - by Industry Chapter 9 Segment Analysis - by Application Chapter 10 Regional Analysis Chapter 11 Competitive Landscape Chapter 12 Company Profiles - Abbott Laboratories - Agilent Technologies Inc - Becton, Dickinson and Company - Bio- Rad Laboratories - Cepheid - Dolomite Centre - Fluidigm Corporation - Johnson & Johnson - Micronit Microfluidics - RainDance Technologies - Roche Diagnostics - Siemens Healthcare For more information visit http://www.researchandmarkets.com/research/x3...crofluidic
Abbott Laboratories (ABT) Breaks Through Resistance at $42.70
Comtex SmarTrend(R) - Tue Aug 26, 10:41AM CDT
Shares of Abbott Laboratories (NYSE:ABT) have bullishly opened above the pivot of $42.49 today and have reached the first resistance level of $42.70. Should the shares continue to rise, the resistance pivots of $42.92 and $43.35 will be of interest.
Collaborations, New Contract, Dividend Declaration, and Capacity Expansion - Research Reports on Abbott, CB&I, Weyerhaeuser, Cardinal Health and SolarCity
PR Newswire - Tue Aug 26, 7:50AM CDT
Today, Analysts Review released its research reports regarding Abbott Laboratories (NYSE: ABT), Chicago Bridge & Iron Company N.V. (NYSE: CBI), Weyerhaeuser Co. (NYSE: WY), Cardinal Health, Inc. (NYSE: CAH) and SolarCity Corporation (NASDAQ: SCTY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5978-100free.
Google's Calico in $500M Joint Venture with AbbVie - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:38PM CDT
Calico, Google's (GOOGL) year-old health startup is collaborating with biotechnology drugmaker, AbbVie, a spin-off from Abbott Laboratories (ABT), for a joint venture to formulate treatments for cancer and Alzheimer's.
Global Companion Diagnostic Technologies Market Opportunities and Forecasts 2013 - 2020
M2 - Thu Sep 04, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qr68q/global_companion) has announced the addition of the "Global Companion Diagnostic Technologies Market (Indication and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. The global companion diagnostic market is expected to reach $3.5 billion by 2020, and it would grow at a CAGR of 20% from 2014 to 2020 Companion diagnostics market by indication is segmented into oncology, cardiovascular, CNS, autoimmune & inflammation, virology and others. Presently, majority of the companion diagnostics have been developed for cancer and thus, it is the major revenue generating segment in the overall CD indication market. Companion diagnostics have been developed for breast cancer, lung cancer, colorectal cancer, gastric cancer and melanomas. Companion diagnostics for breast cancer is the highest revenue generator mainly because there has been an increase in the incidences of breast cancer and many companion diagnostics have been developed for detection of the HER/neu biomarker for breast cancer. As of now, companion diagnostics for cardiovascular conditions, central nervous system conditions , inflammation and autoimmune diseases and viral diseases are very few, with a majority still in development stage; however, as more and more biomarkers are being discovered, there would be an increase in development of new companion diagnostics. Companion diagnostics market by technology is segmented into immmunohistochemistry and molecular diagnostics. Molecular diagnostics has been the most favored technology and it is expected that next generation sequencing and real-time PCR would drive the growth of this market owing to recent advancements in these technologies. KEY DELIVERABLES MARKET BY INDICATIONS - Oncology - Cardiovascular - Central Nervous System - Auto immune & Inflammation - Virology - Others MARKET BY TECHNOLOGY - Immunohistochemistry - Molecular diagnostics - In situ Hybridization - FISH - CISH - Real time PCR - Gene Sequencing COMPANY PROFILES - Abbott Laboratories - bioMerieux - Dako (Agilent Technologies) - Leica Microsystems - Life Technologies - Myriad Genetics - Qiagen - Resonance Health Ltd - Roche - Ventana Medical Systems For more information visit http://www.researchandmarkets.com/research/3q..._companion
RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
Abbott Laboratories Rises 1.26% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Sep 03, 3:57PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $42.35 to a high of $42.79. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $42.60 on volume of 4.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FDA: Little evidence to support testosterone drugs
By MATTHEW PERRONE - AP - Wed Sep 03, 2:18PM CDT
WASHINGTON (AP) — The Food and Drug Administration says there is little evidence that testosterone-boosting drugs taken by millions of American men are beneficial, though the agency is also unconvinced by studies suggesting the hormone carries serious risks.
Google's health startup forges venture with AbbVie
AP - Wed Sep 03, 1:09PM CDT
SAN FRANCISCO (AP) — Google's ambitious health startup is teaming up with biotechnology drugmaker AbbVie in a $500 million joint venture that will try to develop new ways to treat cancer and other diseases such as Alzheimer's.
Global Heart Valve Repair and Replacement Market 2014-2018 - Key Vendors are Abbott Laboratories, Edward Lifesciences, Medtronic & St. Jude Medical
M2 - Wed Sep 03, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4bq7ck/global_heart) has announced the addition of the "Global Heart Valve Repair and Replacement Market 2014-2018" report to their offering. The Global Heart Valve Repair and Replacement market to grow at a CAGR of 7.72 percent over the period 2013-2018. Heart valves are structures in the human heart which control the flow of blood during the cardiac cycle. A person affected with heart valve diseases such as valvular stenosis, valvular insufficiency or regurgitation, prolapse, and atresia requires the repair or replacement of the natural heart valves. Aortic valves cannot be repaired; therefore, it is replaced using prosthetic heart valves. However, the mitral, tricuspid, and pulmonary valves can be repaired as well as replaced depending on the diseased condition and functionality of these valves. Heart valve repair and replacement devices are used for repairing the diseased heart valves as well as for replacing the natural valves with prosthetic valves. One of the emerging trends in the market is the increase in the number of products approved by regulatory authorities such as the FDA and CE. Such products are considered to be safe for commercial use increasing their adoption rate. According to the report, the increase in the aging population is one of the major drivers in the market. The incidence of cardiac disorders is more prevalent among the aging population across the world and people above the age of 60 years affected by heart valve diseases is expected to contribute to the growth the market. Further, the report states that the potential risk of complications associated with the use of heart valve repair and replacement devices is proving to be a barrier to the adoption of these devices. Some of the complications are device migration, infection, thrombosis, and mortality. In terms of application, the Global Heart Valve Repair and Replacement market can be segmented into two: - Heart Valve Repair - Heart Valve Replacement Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Key Vendors - Abbott Laboratories - Edward Lifesciences - Medtronic - St. Jude Medical Other Prominent Vendors - AorTech - Boston Scientific - Colibri Heart Valve - CryoLife - Direct Flow Medical - JenaValve - MiCardia - Mitralign - Neovasc - On-X Life Technologies - Sorin - Symentis - ValveXchange For more information visit http://www.researchandmarkets.com/research/4b...obal_heart
Abbott Receives CE Mark for FreeStyle® Libre, a Revolutionary Glucose Monitoring System for People with Diabetes
PR Newswire - Wed Sep 03, 8:30AM CDT
Abbott (NYSE: ABT) today announced that it has received CE Mark (Conformite Europeenne) for its FreeStyle® Libre Flash Glucose Monitoring System, a revolutionary new glucose sensing technology for people with diabetes. The system eliminates the need for routine finger pricks1, reading glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days. In addition, no finger prick calibration is needed--a key differentiator from current continuous glucose monitoring systems. The system will be available in seven countries across Europe in the coming weeks.
Favourable Rulings, Upcoming Conferences, Clinical Study Results, Drug Availability, and Tender Offers - Research Reports on United Therapeutics, Illumina, AstraZeneca, Eli Lilly and Abbott
PR Newswire - Wed Sep 03, 8:20AM CDT
Today, Analysts Review released its research reports regarding United Therapeutics Corporation (NASDAQ: UTHR), Illumina, Inc. (NASDAQ: ILMN), AstraZeneca plc (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY) and Abbott Laboratories (NYSE: ABT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6174-100free.
LABS, Inc. Names Todd G. Johnson as President and Chief Executive Officer
Business Wire - Tue Sep 02, 2:57PM CDT
LABS, Inc., a Centennial-based comprehensive, highly accredited specialized clinical reference testing laboratory, announced it has appointed Todd G. Johnson, MBA, as President and Chief Executive Officer. Based at LABS, Inc. Centennial headquarters, Johnson's initial priorities will be to continue to grow the company, and ensure that the organization remains competitive within the market place.
Next Support Level for Abbott Laboratories (ABT) is $41.89
Comtex SmarTrend(R) - Tue Sep 02, 12:28PM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today below their pivot of $42.24 and have already reached the first level of support at $42.06. Analysts will be watching for a cross of the next downside pivot targets of $41.89 and $41.54.
Fitch Maintains CFR's IDRs on Rating Watch Positive
Business Wire - Fri Aug 29, 12:47PM CDT
Fitch Ratings maintains CFR Pharmaceuticals S.A. and its subsidiary CFR International SpA on Rating Watch Positive in anticipation of their acquisition by Abbott Investments Luxembourg S.A.R.L., a subsidiary of Abbott Laboratories (Abbott; rated 'A+' by Fitch). A complete list of rating actions follows at the end of this press release.
Drug Discovery Technologies - A Global Market Overview
M2 - Fri Aug 29, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dtdx3f/drug_discovery) has announced the addition of the "Drug Discovery Technologies - A Global Market Overview" report to their offering. The development of new drugs for treating difficult diseases, such as cancer requires extensive expenditure, in addition to consuming a lot of time. The first step in designing a new drug involves the utilizing high-throughput screening of large chemical libraries for identifying compounds that can provide the requisite therapeutic effect. The capability of visualizing biological activity at the cellular level has constituted a strategic component in drug discovery, and adding automation and high-volume screening methods has enabled in testing compounds in large numbers. The field of pharmaceutical research is being provided considerable impetus through the combination of imaging and screening. Key Topics Covered: PART A: GLOBAL MARKET PERSPECTIVE 1. INTRODUCTION 2. KEY MARKET TRENDS 3. RECENT PATENTS IN DRUG DISCOVERY LANDSCAPE 4. KEY GLOBAL PLAYERS 5. KEY BUSINESS TRENDS 6. GLOBAL MARKET OVERVIEW PART B: REGIONAL MARKET PERSPECTIVE 1. THE UNITED STATES 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART C: GUIDE TO THE INDUSTRY 1. NORTH AMERICA 2. EUROPE 3. ASIA-PACIFIC 4. REST OF WORLD PART
ANNEXURE 1. RESEARCH METHOLOGY 2. FEEDBACK Companies Mentioned: - 4-Antibody AG - Abbott Laboratories - Accelrys, Inc. - Affymetrix Inc. - Agilent Technologies Inc. - Asahi Kasei Pharma Corporation - Astrazeneca Plc - Aviva Biosciences Corp. - Bayer Healthcare AG - BD Biosciences - Beckman Coulter Inc. - Biacore International AB - Bioanalytical Systems, Inc. - Bio-Rad Laboratories, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Caliper Life Sciences, Inc. - Caprion Proteomics, Inc. - Celera Corporation - Celgene Corporation - Charles River Laboratories International, Inc. - Compugen Ltd. - Decode Genetics, Inc. - EMD Millipore Corporation - Evotec AG - GE Healthcare Ltd. - Genedata AG - Hitgen Ltd - Hudson Robotics, Inc. - Illumina Inc. - Incyte Corporation - Isis Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Luminex Corporation - Maxcyte, Inc - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Molecular Devices, LLC - Molecular Discovery Ltd. - Molecular Discovery Systems Pty., Ltd. - New England Biolabs, Inc. - Novartis AG - Osiris Therapeutics Inc. - Perkinelmer, Inc. - Promega Corporation - Qiagen N.V. - Quantum Pharmaceuticals - Roche Holding AG - Shimadzu Corporation - Sigma-Aldrich Corporation - Sri Biosciences - Tecan Group Ltd. - The National Center for Drug Screening - Thermo Fisher Scientific Inc. - Viva Biotech Ltd - Waters Corp. For more information visit http://www.researchandmarkets.com/research/dt..._discovery Global Infant Formula Market Report: Focus on China 2014
M2 - Thu Aug 28, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/twqn7f/global_infant) has announced the addition of the "Global Infant Formula Market Report: Focus on China" report to their offering. The market for infant formula products is one of the major and the fastest growing segments of the overall baby foods industry. Infant formula is either a partial or a total substitute for breast milk for infants and is recommended for feeding during the first twelve months. Since the start of the millennium, international awareness regarding the importance of early childhood nutrition has been on the rise. All over the world parents are becoming more concerned about the nutritional benefit of pediatric foods and breast-milk supplements. Increasing proportion of women participation in labor force and increased affordability supported by waning price responsiveness and a rise in disposable income across the world are the major factors that have helped the global IMF market to attain stronger growth levels. Though the market has been experiencing lower demand and growth from the traditional matured markets of the West stemming primarily from declining birth rate, the developing world, especially the Asia and Pacific region and Latin America have provided the headroom for the global market expansion. The market is dominated by the Asian region which consumes about three-fifths of the global IMF supplies. Particularly, China has gained the stature to maneuver the market single-handedly since the country alone accounts for about two-fifth of the global IMF market revenues. The report, Global Infant Formula Market prudently analyzes the development of the respective market, with a focus on the single largest market, China, and other regional but important markets. The report discusses the major trends, growth drivers as well as issues being faced by the industry. The global infant formula market is predominated by a handful of players including Nestl?, Danone, Mead Johnson Nutrition and Abbott which keep vying for greater market share. The profiles of these leading players are also included in the report along with their key financials and strategies for growth. . Key Topics Covered: 1. Market Overview 2. Baby Food/Infant Nutrition Market 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Abbott Laboratories - Danone S.A. - Mead Johnson Nutrition Co. - Nestl? S.A. For more information visit http://www.researchandmarkets.com/research/tw...bal_infant
Frustrating Boston Scientific Is Not What the Investor Ordered
at The Street - Thu Aug 28, 5:30AM CDT
It will only take one bad quarter for shares to fall to single digits. That's the only time you should buy.
Abbott Laboratories Has Returned 10.4% Since SmarTrend Recommendation (ABT)
Comtex SmarTrend(R) - Wed Aug 27, 10:05AM CDT
SmarTrend identified an Uptrend for Abbott Laboratories (NYSE:ABT) on April 22nd, 2014 at $38.75. In approximately 4 months, Abbott Laboratories has returned 10.39% as of today's recent price of $42.77.
Home Healthcare Global Market Report - Forecast to 2020 for the $300 Million Industry
M2 - Wed Aug 27, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lbsmjs/home_healthcare) has announced the addition of the "Home Healthcare Global Market - Forecast to 2020" report to their offering. Global home healthcare market is expected to reach more than $300 billion by 2019 growing at a CAGR of around 8.0% from 2014 to 2019 The home healthcare equipment market is expected to grow at a faster rate compared to home healthcare services market. Home healthcare is gaining a tremendous attention over hospitals for the sophistication, ease and privacy of treatment it offers. Increased in-hospital care cost, comfort of recovering at home and enhanced age-related chronic diseases in developing as well as developed countries are factors driving the overall growth of home healthcare market. Whereas factors such as poor technology adoption, weak reimbursement policies and rapidly changing technologies are hampering the market growth. Moreover, high capital costs, medical equipment, human resources and conventional model of business are the challenges faced by home healthcare market. The opportunities increasing the market trend is attributed to medical insurance by governments or organizations and cost-effectiveness.North America adopting novel technologies and portable diagnostic devices accounts for the largest share in the home healthcare market. While Europe with the presence of well-equipped healthcare reimbursement structure is the second leading market. Asia-Pacific is expected to grow at the highest CAGR driven by the aging population in countries such as India, China, and Japan. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Home Healthcare Therapeutic Equipment Market 5. Home Healthcare Services Market 6. Home Healthcare Telehealth Market 7. Regional Market Analysis 8. Company Developments 9. Major Company Profiles - Abbott Laboratories - Baxter International - Braun - Novo Nordisk - GE Healthcare - Invacare - Johnson and Johnson - Medtronic - Philips Healthcare - Roche Holding AG For more information visit http://www.researchandmarkets.com/research/lb...healthcare
Microfluidic Device System Market 2013 - 2019
M2 - Wed Aug 27, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x345bg/microfluidic) has announced the addition of the "Microfluidic Device System Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The global microfluidic device market was valued at USD 1,531.2 million in 2013. It is likely to grow at a CAGR of 22.8% during 2013 to 2019 to reach USD 5,246.4 million in 2019. Microfluidics is an evolving scientific field with numerous analytical applications and commercial potential. Globally, the microfluidic device market is witnessing significant growth due to increasing R&D investment in pharmaceuticals, life science and rising point of care testing demand. New trends in healthcare, such as healthcare at home, supports point of care testing (POCT) as the most efficient and effective delivery of healthcare. It has many applications in other areas such as drug screening, sugar testers, chemical micro reactor, microprocessor cooling and micro fuel cells. Rising demand for point of care testing, miniaturization of chip, and increasing demand for microfluidic devices in genomics and proteomics are the key growth drivers for the microfluidic device market. In addition, change in material mix would provide opportunity for new market entrants, which would further drive the growth of the microfluidic device market. North America was valued at USD 644.5 million in 2013 and is expected to reach USD 2,095.5 million in 2019, growing at a CAGR of 21.7% from 2013 to 2019. In-vitro diagnostics microfluidic device market was valued at USD 949.6 million in 2013 and is expected to reach USD 3,317.4 million in 2019, growing at a CAGR of 23.2% from 2013 to 2019. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Industry Analysis Chapter 4 Market Trends Chapter 5 Porters Five Force Analysis Chapter 6 Global Market Size and Forecast Chapter 7 Segment Analysis - by Material Chapter 8 Segment Analysis - by Industry Chapter 9 Segment Analysis - by Application Chapter 10 Regional Analysis Chapter 11 Competitive Landscape Chapter 12 Company Profiles - Abbott Laboratories - Agilent Technologies Inc - Becton, Dickinson and Company - Bio- Rad Laboratories - Cepheid - Dolomite Centre - Fluidigm Corporation - Johnson & Johnson - Micronit Microfluidics - RainDance Technologies - Roche Diagnostics - Siemens Healthcare For more information visit http://www.researchandmarkets.com/research/x3...crofluidic
Abbott Laboratories (ABT) Breaks Through Resistance at $42.70
Comtex SmarTrend(R) - Tue Aug 26, 10:41AM CDT
Shares of Abbott Laboratories (NYSE:ABT) have bullishly opened above the pivot of $42.49 today and have reached the first resistance level of $42.70. Should the shares continue to rise, the resistance pivots of $42.92 and $43.35 will be of interest.
Collaborations, New Contract, Dividend Declaration, and Capacity Expansion - Research Reports on Abbott, CB&I, Weyerhaeuser, Cardinal Health and SolarCity
PR Newswire - Tue Aug 26, 7:50AM CDT
Today, Analysts Review released its research reports regarding Abbott Laboratories (NYSE: ABT), Chicago Bridge & Iron Company N.V. (NYSE: CBI), Weyerhaeuser Co. (NYSE: WY), Cardinal Health, Inc. (NYSE: CAH) and SolarCity Corporation (NASDAQ: SCTY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5978-100free.
